Clinical trialObservationalTerminated
Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer
- Outcome
- Stopped earlyEnrollment stopped early on May 31, 2024, because of slow accrual, an unexpectedly high rate of postoperative drop-out and a low rate of ctDNA-positive patients. (Enrollment)
- Phase
- Observational
- Status
- Terminated
- Study type
- Observational
- Start
- 22 December 2020
- Ended
- 2 June 2025
- Enrollment
- 112 participants
- Sites
- 6
- Primary outcomes
- Disease-free survival (DFS)
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 17 November 2026
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
PROJECTION is a non-randomized, multicenter, non-interventional cohort study in patients with resectable pancreatic ductal adenocarcinoma (PDAC). Patients are allocated to two observation groups according to the preoperative presence (Group A) or absence (Group B) of circulating tumor DNA (ctDNA) in a liquid biopsy analyzed with FoundationOne Liquid CDx. After surgery and completion of local histological evaluation, tumor tissue is analyzed with FoundationOne CDx. Earlier protocol versions also included a second liquid biopsy within 14 days before the start of adjuvant chemotherapy. Patients are followed for recurrence according to institutional standards about every three months for the first 18 months after surgery and about every six months thereafter, until recurrence or death, for a maximum of 36 months after surgery and until May 31, 2025 at the latest. Enrollment was stopped on May 31, 2024.